Inactivation of CYP2D6 by Berberrubine and the Chemical Mechanism

被引:0
|
作者
Rao, Jinqiu [1 ,2 ,3 ]
Wang, Tianwang [1 ,2 ,3 ]
Yu, Leran [1 ]
Wang, Kai [1 ,2 ]
Qiu, Feng [1 ,2 ,3 ]
机构
[1] Tianjin Univ Tradit Chinese Med, Sch Chinese Mat Med, Tianjin 301617, Peoples R China
[2] Tianjin Univ Tradit Chinese Med, Tianjin Key Lab Therapeut Subst Tradit Chinese Med, Tianjin 301617, Peoples R China
[3] Tianjin Univ Tradit Chinese Med, State Key Lab Component Based Chinese Med, Tianjin 301617, Peoples R China
基金
中国国家自然科学基金;
关键词
IN-VITRO; DRUG-INTERACTIONS; METABOLISM; BERBERINE; INHIBITION; PHARMACOKINETICS; BUPROPION; RELEVANCE; P450;
D O I
10.1021/acs.biochem.4c00450
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Berberrubine (BRB), belonging to the benzylisoquinoline alkaloid, is a main metabolite of berberine in vivo. BRB was previously proven to undergo metabolic activation mediated by P450s. In this study, the chemical interactions between BRB and CYP2D6 enzyme were investigated. First, a variety of P450s participated in the metabolism of berberine transformed to BRB, but CYP2D6 was the most involved enzyme. A time-, concentration-, and nicotinamide adenine dinucleotide phosphate (NADPH)-dependent inhibition of CYP2D6 was caused by BRB. The inhibitory effect of BRB on CYP2D6 was irreversible. The maximum reaction rate constants of inactivation (k inact) and half-maximal inactivation (K I) of BRB on CYP2D6 were 0.0410 min-1 and 3.798 mu M, respectively. Metoprolol, a classic substrate of CYP2D6, attenuated CYP2D6 from inactivation by BRB. Glutathione (GSH) and catalase/superoxide dismutase failed to protect against the inactivation of CYP2D6 caused by BRB. Three cys-based adducts derived from the reaction of electrophilic metabolites of BRB with CYP2D6 were detected by ultra performance liquid chromatography-mass spectrometry (UPLC-MS)/MS. The reactive metabolites derived from BRB might be responsible for the inactivation of CYP2D6. In summary, BRB was characterized as a mechanism-based inactivator of CYP2D6.
引用
收藏
页码:3078 / 3089
页数:12
相关论文
共 50 条
  • [21] Docking and molecular dynamics studies on CYP2D6
    Wang JingFang
    Zhang ChengCheng
    Wei DongQing
    Li YiXue
    CHINESE SCIENCE BULLETIN, 2010, 55 (18): : 1877 - 1880
  • [22] Synthetic strategies to lower affinity for CYP2D6
    Halliday, RC
    Jones, BC
    Park, BK
    Smith, DA
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1997, 22 (04) : 291 - 294
  • [23] Enantioselective metabolism of primaquine by human CYP2D6
    Fasinu, Pius S.
    Tekwani, Babu L.
    Nanayakkara, N. P. Dhammika
    Avula, Bharathi
    Herath, H. M. T. Bandara
    Wang, Yan-Hong
    Adelli, Vijender R.
    Elsohly, Mahmoud A.
    Khan, Shabana I.
    Khan, Ikhlas A.
    Pybus, Brandon S.
    Marcsisin, Sean R.
    Reichard, Gregory A.
    McChesney, James D.
    Walker, Larry A.
    MALARIA JOURNAL, 2014, 13
  • [24] The inhibition of CYP1A2, CYP2C9, and CYP2D6 by pterostilbene in human liver microsomes
    Albassam, A. A.
    Ahad, A.
    Alsultan, A.
    Yusufoglu, H. S.
    Foudah, A., I
    Al-Jenoobi, F., I
    PHARMAZIE, 2021, 76 (04): : 155 - 158
  • [25] Substrate specificity of CYP2D6 genetic variants
    van der Lee, Maaike
    Guchelaar, Henk-Jan
    Swen, Jesse J.
    PHARMACOGENOMICS, 2021, 22 (16) : 1081 - 1089
  • [26] The CYP2D6 VCF Translator
    Qiao, W.
    Wang, J.
    Pullman, B. S.
    Chen, R.
    Yang, Y.
    Scott, S. A.
    PHARMACOGENOMICS JOURNAL, 2017, 17 (04) : 301 - 303
  • [27] Use of CYP2D6 Inhibitors with CYP2D6 Opioids: Association with Emergency Department Visits for Pain
    Nahid, Noor Ahmed
    McDonough, Caitrin W.
    Wei, Yu-Jung Jenny
    Cicali, Emily J.
    Gong, Yan
    Fillingim, Roger B.
    Johnson, Julie A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 116 (04) : 1005 - 1012
  • [28] The Effects of Puerarin on CYP2D6 and CYP1A2 Activities In Vivo
    Zheng, Jiao
    Chen, Bin
    Jiang, Bing
    Zeng, Ling
    Tang, Zhi-Rong
    Fan, Lan
    Zhou, Hong-Hao
    ARCHIVES OF PHARMACAL RESEARCH, 2010, 33 (02) : 243 - 246
  • [29] Mechanism-based inactivation of cytochrome P450 2D6 by chelidonine
    Liu, Yuyang
    Cui, Tiantian
    Peng, Ying
    Ji, Mingshan
    Zheng, Jiang
    JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 2019, 33 (02)
  • [30] CYP2D6 pharmacogenetics and risperidone: reflections after 25 years of research
    de Leon, Jose
    Schoretsanitis, Georgios
    PHARMACOGENOMICS, 2020, 21 (16) : 1139 - 1144